Table 2.
Study quality report
| Author (year) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Karlsson et al. (2010) | + | + | + | − | + | − | + | − | + | + | 7 |
| Lie et al. (2010) | + | + | + | − | + | + | + | + | − | + | 8 |
| Boengler and Hilfiker-Kleiner (2010) | + | − | − | − | + | − | + | − | − | − | 3 |
| Skychally et al. (2010) | + | + | − | − | − | − | + | − | − | − | 3 |
| Matsubara et al. (2010) | + | − | − | − | + | + | + | − | − | − | 4 |
| Dow and Kloner (2007) | + | + | − | − | − | − | − | + | − | − | 3 |
| Pagel and Krolikowski (2009) | + | + | − | − | + | + | − | − | − | − | 4 |
| Gomez et al. (2008) | + | + | − | − | + | + | + | − | − | + | 6 |
| Fang et al. (2008) | + | + | − | − | + | − | + | − | − | − | 4 |
| Leshnower et al. (2008) | + | − | − | − | + | + | + | − | − | − | 4 |
| Huhn et al. (2008) | + | − | − | − | + | − | + | − | − | − | 3 |
| Lim et al. (2007) | + | − | − | − | + | + | + | − | − | − | 4 |
| Xie and Yu (2007) | + | + | − | − | − | + | + | − | − | − | 4 |
| Ikeda et al. (2006) | + | + | − | − | + | − | + | − | − | − | 4 |
| Wang et al. (2006) | + | + | − | − | + | + | − | − | − | − | 4 |
| Argaud et al. (2005a) | + | + | − | − | + | − | + | − | − | − | 4 |
| Krolikowski et al. (2005) | + | + | − | − | + | + | − | − | − | − | 4 |
| Argaud et al. (2004) | + | + | − | − | + | − | + | − | − | − | 4 |
| Niemann et al. (2002) | + | + | − | − | + | − | − | − | − | − | 3 |
| Squadrito et al. (1999) | + | + | − | − | − | − | − | − | − | − | 2 |
Study quality items are: (1) Publication in a peer-reviewed journal; (2) Randomization to either treatment with cyclosporin or placebo control; (3) Blinded assessment of outcome; (4) Use of animal models with co-morbidity; (5) Statement of compliance with regulatory requirement; (6) Method of confirmation of ischemia; (7) Statement of control of temperature; (8) Sample size calculation; (9) Blinded induction of ischaemia; and (10) Statement of conflict of interest.